title: Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
abstract: The clonal immunoglobulin idiotype displayed on the surface of most malignant B cells is a patient- and tumour-specific antigen that can be used for therapeutic vaccination. Several studies have confirmed the biological efficacy of soluble protein idiotypic vaccination and two clinical trials have shown the clinical efficacy of this procedure. One study has demonstrated clinical benefit associated with idiotypic vaccination. However, three randomized clinical trials have recently failed to achieve their main end points for reasons that are probably unrelated to the vaccine. While scepticism towards this type of non-toxic medical intervention is mounting, such patient-specific treatments might yet see the light of day through better designed clinical trials.
authors.affiliation: Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain. mbendandi@unav.es
authors.forename: Maurizio
authors.initials: M
authors.lastname: Bendandi
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes
references.citation: J Immunol. 2008 Sep 15;181(6):4131-40
references.pmid: 18768870
references.citation: Leuk Lymphoma. 2009 Jan;50(1):47-53
references.pmid: 19152172
references.citation: Mol Immunol. 2009 Jan;46(3):448-56
references.pmid: 19046770
references.citation: J Clin Invest. 2004 May;113(10):1498-510
references.pmid: 15146248
references.citation: N Engl J Med. 2004 Nov 18;351(21):2159-69
references.pmid: 15548776
references.citation: J Biol Chem. 2007 Mar 9;282(10):7405-15
references.pmid: 17197448
references.citation: Nature. 1975 Apr 24;254(5502):714-6
references.pmid: 47617
references.citation: J Clin Oncol. 2007 Feb 10;25(5):579-86
references.pmid: 17242396
references.citation: J Immunol. 1990 Aug 1;145(3):1029-36
references.pmid: 2373859
references.citation: N Engl J Med. 1992 Oct 22;327(17):1209-15
references.pmid: 1406793
references.citation: Expert Rev Vaccines. 2009 Jan;8(1):43-50
references.pmid: 19093772
references.citation: J Immunol. 1987 Jan 15;138(2):628-34
references.pmid: 3491853
references.citation: CA Cancer J Clin. 2008 Sep-Oct;58(5):305-17
references.pmid: 18755938
references.citation: Blood. 2004 Oct 1;104(7):1961-9
references.pmid: 15191951
references.citation: J Immunol. 1987 Feb 15;138(4):1289-96
references.pmid: 3492546
references.citation: J Clin Oncol. 2004 Dec 1;22(23):4717-24
references.pmid: 15483014
references.citation: N Engl J Med. 2003 Jun 26;348(26):2609-17
references.pmid: 12826635
references.citation: J Immunol Methods. 1986 May 1;89(1):61-72
references.pmid: 3084658
references.citation: Proc Natl Acad Sci U S A. 1971 Dec;68(12):3130-5
references.pmid: 4108872
references.citation: Blood. 1997 May 1;89(9):3129-35
references.pmid: 9129015
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3107-12
references.pmid: 16754937
references.citation: Haematologica. 2004 May;89(5):541-6
references.pmid: 15136216
references.citation: J Clin Oncol. 1995 Jan;13(1):140-7
references.pmid: 7799014
references.citation: Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10972-7
references.pmid: 8855293
references.citation: Br J Haematol. 2008 Jun;142(2):179-91
references.pmid: 18422783
references.citation: N Engl J Med. 1985 Jun 27;312(26):1653-8
references.pmid: 3923351
references.citation: N Engl J Med. 1985 Jun 27;312(26):1658-65
references.pmid: 3923352
references.citation: Blood. 2002 Apr 1;99(7):2562-8
references.pmid: 11895794
references.citation: Expert Rev Vaccines. 2004 Apr;3(2):163-70
references.pmid: 15056042
references.citation: Leukemia. 2000 Aug;14(8):1333-9
references.pmid: 10942225
references.citation: Blood. 2009 Jun 4;113(23):5743-6
references.pmid: 19346494
references.citation: Blood Rev. 2009 May;23(3):137-42
references.pmid: 18951668
references.citation: Leuk Lymphoma. 2009 Jan;50(1):1-2
references.pmid: 19172492
references.citation: J Natl Cancer Inst. 2006 Sep 20;98(18):1263-5
references.pmid: 16985240
references.citation: J Immunother. 2008 Apr;31(3):310-2
references.pmid: 18317357
references.citation: Haematologica. 2003 Dec;88(12):1438-40
references.pmid: 14688006
references.citation: Blood. 1998 Aug 15;92(4):1184-90
references.pmid: 9694706
references.citation: Nat Med. 2005 Sep;11(9):986-91
references.pmid: 16116429
references.citation: Nat Med. 1999 Oct;5(10):1171-7
references.pmid: 10502821
references.citation: Leuk Lymphoma. 2009 Jan;50(1):37-46
references.pmid: 19125383
references.citation: Eur Urol. 2000;37 Suppl 3:24-33
references.pmid: 10828684
references.citation: Proc Natl Acad Sci U S A. 1972 Jun;69(6):1540-4
references.pmid: 4113870
references.citation: J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301
references.pmid: 16985248
references.citation: Rev Recent Clin Trials. 2006 Jan;1(1):67-74
references.pmid: 18393782
references.citation: J Clin Oncol. 2009 Jun 20;27(18):3036-43
references.pmid: 19414675
references.citation: Blood. 2007 Feb 1;109(3):951-3
references.pmid: 17032925
references.citation: Crit Rev Oncol Hematol. 2004 Oct;52(1):1-7
references.pmid: 15363462
references.citation: J Natl Cancer Inst. 2003 Jun 18;95(12):845
references.pmid: 12813164
references.citation: Expert Rev Anticancer Ther. 2001 Jun;1(1):65-72
references.pmid: 12113135
references.citation: Vaccine. 2009 Jan 7;27(2):250-9
references.pmid: 19000731